🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are on the rise globally, with estimates suggesting in excess of 82 million instances annually. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the context of rising global incidence, the spread of superbugs and the very limited therapeutic options currently available.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Authorization

Zoliflodacin, also known as a brand name, was authorized by the American regulatory agency in December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug successfully treated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which combines two antibiotics. The research involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the rights to make available and distribute the drug in many low-income and middle-income countries.

Doctors directly involved have voiced hope. The availability of a easy-to-administer therapy such as this is hailed as a "revolutionary step" for public health efforts. This is considered crucial to alleviate the strain of the infection for people and to stop the proliferation of extremely resistant gonorrhoea globally.